Abstract
In China, intravenous belimumab is listed for the treatment of SLE1; however, no evaluation of its cost-effectiveness exists. We estimated the cost-effectiveness of belimumab plus standard therapy (ST) versus ST alone, among patients with SLE, from the government payer perspective in China.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.